Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-623 (Blisibimod) in Systemic Lupus Erythematosus
NCT01162681Phase 2Completed
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Jul 2010
- Primary completion
- Apr 2012
- Modality
- Fc-Fusion Proteins
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of blisibimod in systemic lupus erythematosus (SLE) (4 arms), sponsored by Anthera Pharmaceuticals, Inc. Primary endpoint: SLE response at 52 weeks. Started Jul 2010; status: completed.
02
Drugs
blisibimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01162681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01162681.